Supplementary Table 1. Time to hospital discharge who received combination therapy as compared with monotherapy (ITT)

	Monotherapy $(n = 56)$	Combination therapy $(n = 61)$	Sub-distribution hazard ratio (95% CI)	P value*
Primary endpoints				
Hospital discharge				
At 7 days	3.6% (0.9%- 13.5%)	8.6% (3.7%- 19.5%)		
At 14 days	85.7% (75.3%- 93.3%)	82.8% (72.1%- 91.1%)		
At 21 days	94.6% (86.6%- 98.6%)	89.7% (80.3%- 95.8%)		
Competing risk analysis				
Time to hospital discharge			1.444 (1.008- 2.069)	0.045

CI, confidence interval.

## Supplementary Table 2. Time to hospital discharge who received combination therapy as compared with monotherapy (PPS)

	Monotherapy	Combination therapy	Hazard ratio (95% CI)	P value*
Primary endpoints				
Time to hospital			1.817	
discharge, median (95%CI) (days)	11 (10-12)	10 (9-11)	(1.072- 3.080)	0.025
Hospital discharge				
At 7 days	4.2% (1.1%-15.6%)	8.2% (3.1%-20.3%)		
At 14 days	83.3% (7.8%-28.4%)	87.8% (77.0%-95.0%)		
At 21 days	93.8% (84.5%-98.4%)	93.9% (84.8%-98.4%)		

CI, confidence interval; PPS, per-protocol set.

## Supplementary Table 3: Summary of Adverse Events by System Organ Class (SOC) and Preferred Term (PT)

		Monotherapy group	Monotherapy group			Polypharmacy therapy group		
		N = 56		N = 61				
SOC	PT	Number of Patients events	Incidence (%)*	Number of events	Number of Patients	Incidence (%)*		

<sup>\*</sup> Wald p-value from stratified Fine-Gray model.

<sup>\*</sup> Stratified log-rank test.

All adverse events		42	32	57·1	39	34	55.7
Gastrointestinal disorders		0	0	0.0	3	1	1.6
	nausea	0	0	0.0	1	1	1.6
	vomiting	0	0	0.0	2	1	1.6
Infectious diseases and parasites		1	1	1.8	1	1	1.6
	Oral candidiasis	0	0	0.0	1	1	1.6
	cystitis	1	1	1.8	0	0	0.0
Hepatobiliary system disorder		4	4	7.1	1	1	1.6
	Liver dysfunction	4	4	7.1	1	1	1.6
Respiratory, thoracic, and mediastinal disorders		1	1	1.8	1	1	1.6
	Pulmonary embolism	1	1	1.8	0	0	0.0
	Vocalization disorder	0	0	0.0	1	1	1.6
Nervous system disorders		2	1	1.8	0	0	0.0
	Headache	1	1	1.8	0	0	0.0
	Floating dizziness	1	1	1.8	0	0	0.0
Metabolic and nutritional disorders		0	0	0.0	1	1	1.6
	Hyponatremia	0	0	0.0	1	1	1.6
Skin and subcutaneous tissue disorders		2	2	3.6	0	0	0.0
	Itching	1	1	1.8	0	0	0.0
	rash	1	1	1.8	0	0	0.0
Laboratory test		32	29	51.8	32	32	52.5
, ,	Fibrin D-		-				
	dimer increase Liver	1	1	1.8	0	0	0.0
	function test abnormalities Liver	0	0	0.0	1	1	1.6
	function test value increase	2	2	3.6	0	0	0.0
	Increased blood glucose Increased	0	0	0.0	1	1	1.6
	blood uric	29	28	50.0	30	30	49.2

PT: Preferred term; SOC: System Organ Class.